You have read all your free articles, to continue reading subscribe to read the rest of this content.
AstraZeneca announces that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Tagrisso (osimertinib) for the 1st-line treatment of patients with inoperable or recurrent epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC), following prioAlready a subscriber Login You have read all your free articles, to continue reading…
Novo Nordisk has announced plans to invest DKK 850 million in expanding its production facilities in Kalundborg, Denmark. This new investment brings Novo Nordisk’s total investments in site Kalundborg to more than DKK 2 billion in 2020. Novo Nordisk currently manufactures a range of diabetes caAlready a subscriber Login You…
Farxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the US to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease (ESKD), cardiovascular (CV) death and hospitalisation for heart failure (hHF) in adulAlready a subscriber Login You have read all your free…
AstraZeneca and Medimmune, AstraZeneca PLC’s global biologics research and development unit, gave a presentation on the company’s pipeline in the area of immuno-oncology at the recent American Society of Clinical Oncology meeting. Immuno-oncology involves programming or stimulating the bodyAlready a subscriber Login You have read all your free articles, to continue reading…
